|
|||||
|
|
Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studies |
|
| Authors: | Richard Pratley MD Samuel Dagogo-Jack MD Bernard Charbonnel MD Shrita Patel MD Anne Hickman DVM Jie Liu MD Lisa Tarasenko PharmD Annpey Pong PhD Misoo C. Ellison PhD Susan Huyck DrPH Ira Gantz MD Steven G. Terra PharmD |
| Affiliation: | 1. AdventHealth Translational Research Institute for Metabolism and Diabetes, Orlando, Florida, USA;2. University of Tennessee Health Science Center, Memphis, Tennessee, USA;3. University of Nantes, Nantes, France;4. Merck & Co., Inc., Kenilworth, New Jersey, USA;5. Pfizer Inc., Groton, Connecticut, USA;6. Pfizer Inc., New York, New York, USA;7. Pfizer Inc., Andover, Massachusetts, USA |
| Abstract: | |
| Keywords: | antidiabetic drug diabetes complications glycaemic control observational study SGLT2 inhibitor type 2 diabetes |